 comparative trial doxorubicin treatment malignant pleural effusion secondary lung cancer efficacy safety intrapleural Yakult Tokyo Japan doxorubicin Adriamycin Adria Columbus OH randomized trial patients malignant pleural effusions lung cancer Seventy-six patients eligible assessment efficacy response rate treatment intrapleural doxorubicin patients response rate control group doxorubicin patients group improvement performance status PS symptoms pain chest discomfort anorexia control group significant prolongation survival group main side effects transient hepatic dysfunction serious adverse reactions results intrapleural instillation treatment malignant pleural effusions